Literature DB >> 33475738

The balancing act in Burkitt lymphoma.

Mark Roschewski1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33475738      PMCID： PMC7819758          DOI： 10.1182/blood.2020008091

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.

Authors:  Mitchell S Cairo; Richard Sposto; Mary Gerrard; Anne Auperin; Stanton C Goldman; Lauren Harrison; Ross Pinkerton; Martine Raphael; Keith McCarthy; Sherrie L Perkins; Catherine Patte
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

2.  Central nervous system involvement in Burkitt's lymphoma.

Authors:  J L Ziegler; A Z Bluming; R H Morrow; L Fass; P P Carbone
Journal:  Blood       Date:  1970-12       Impact factor: 22.113

3.  Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

Authors:  Mark Roschewski; Kieron Dunleavy; Jeremy S Abramson; Bayard L Powell; Brian K Link; Prapti Patel; Philip J Bierman; Deepa Jagadeesh; Ronald T Mitsuyasu; David Peace; Peter R Watson; Wahid T Hanna; Christopher Melani; Andrea N Lucas; Seth M Steinberg; Stefania Pittaluga; Elaine S Jaffe; Jonathan W Friedberg; Brad S Kahl; Richard F Little; Nancy L Bartlett; Michelle A Fanale; Ariela Noy; Wyndham H Wilson
Journal:  J Clin Oncol       Date:  2020-05-26       Impact factor: 44.544

4.  Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.

Authors:  Janina Salzburg; Birgit Burkhardt; Martin Zimmermann; Olga Wachowski; Wilhelm Woessmann; Ilske Oschlies; Wolfram Klapper; Hans-Heinrich Wacker; Wolf-Dieter Ludwig; Felix Niggli; Georg Mann; Helmut Gadner; Hansjoerg Riehm; Martin Schrappe; Alfred Reiter
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

5.  Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.

Authors:  Eunice S Wang; David J Straus; Julie Teruya-Feldstein; Jing Qin; Carol Portlock; Craig Moskowitz; Andre Goy; Eric Hedrick; Andrew D Zelenetz; Ariela Noy
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

6.  Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

Authors:  Jennifer L Kelly; Stephen R Toothaker; Lauren Ciminello; Dieter Hoelzer; Harald Holte; Ann S LaCasce; Graham Mead; Deborah Thomas; Gustaaf W Van Imhoff; Brad S Kahl; Bruce D Cheson; Ian T Magrath; Richard I Fisher; Jonathan W Friedberg
Journal:  Clin Lymphoma Myeloma       Date:  2009-08

7.  An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

Authors:  G M Mead; M R Sydes; J Walewski; A Grigg; C S Hatton; N Pescosta; C Guarnaccia; M S Lewis; J McKendrick; S P Stenning; D Wright; P Norbert
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

8.  AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.

Authors:  Ariela Noy; Jeannette Y Lee; Ethel Cesarman; Richard Ambinder; Robert Baiocchi; Erin Reid; Lee Ratner; Nina Wagner-Johnston; Lawrence Kaplan
Journal:  Blood       Date:  2015-05-08       Impact factor: 22.113

9.  Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.

Authors:  Andrew M Evens; Alexey Danilov; Deepa Jagadeesh; Amy Sperling; Seo-Hyun Kim; Ryan Vaca; Catherine Wei; Daniel Rector; Suchitra Sundaram; Nishitha Reddy; Yong Lin; Umar Farooq; Christopher D'Angelo; David A Bond; Stephanie Berg; Michael C Churnetski; Amandeep Godara; Nadia Khan; Yun Kyong Choi; Maryam Yazdy; Emma Rabinovich; Gaurav Varma; Reem Karmali; Agrima Mian; Malvi Savani; Madelyn Burkart; Peter Martin; Albert Ren; Ayushi Chauhan; Catherine Diefenbach; Allandria Straker-Edwards; Andreas K Klein; Kristie A Blum; Kirsten Marie Boughan; Scott E Smith; Brad M Haverkos; Victor M Orellana-Noia; Vaishalee P Kenkre; Adam Zayac; Jeremy Ramdial; Seth M Maliske; Narendranath Epperla; Parameswaran Venugopal; Tatyana A Feldman; Stephen D Smith; Andrzej Stadnik; Kevin A David; Seema Naik; Izidore S Lossos; Matthew A Lunning; Paolo Caimi; Manali Kamdar; Neil Palmisiano; Veronika Bachanova; Craig A Portell; Tycel Phillips; Adam J Olszewski; Juan Pablo Alderuccio
Journal:  Blood       Date:  2021-01-21       Impact factor: 22.113

10.  Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.

Authors:  J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 11.816
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.